Related Experiment Video
Updated: Aug 5, 2026

Assessment of Kidney Function in Mouse Models of Glomerular Disease
Published on: June 30, 2018
Assessing laboratory performance for markers of kidney injury/function: a retrospective study based on External
José Antonio Tesser Poloni1, Adriana Vieira1, Rafael Monsores Lopes1
1Controllab, Rio de Janeiro, RJ, Brazil.
Background:
Chronic kidney disease (CKD) and acute kidney injury (AKI) affect over 850 million individuals worldwide, with diagnosis and management heavily dependent on laboratory biomarkers. Reliable assessment of kidney biomarkers is therefore essential. External Quality Assessment (EQA) plays a critical role in ensuring the accuracy and comparability of results across laboratories.
Methods:
We retrospectively analyzed EQA data from a Brazilian proficiency testing provider (January 2009-March 2024). Reported results for serum creatinine, urinary creatinine, urinary albumin, and total urinary proteins were evaluated. Coefficients of variation (CVs) and adequacy percentages (%Adequacy) were compared across methods using the Kruskal-Wallis test. Trends were assessed with the Mann-Kendall test.
Results:
For serum and urinary creatinine, amidinohydrolase/oxidase methods consistently showed the lowest CVs (~3-4.5%) compared with Jaffé-based methods. For urinary albumin, turbidimetry demonstrated superior performance (~5.0% CV), while for total urinary proteins, benzethonium chloride methods yielded the best results (~5.0% CV). Across all biomarkers, CVs decreased and %Adequacy increased significantly over the 15-year period, particularly at clinically relevant concentrations. Nevertheless, Jaffé-based creatinine methods remained predominant despite their well-documented specificity limitations.
Conclusion:
Over 15 years, participant laboratories improved the precision and adequacy of kidney biomarker measurements in EQA programs. However, persistent reliance on outdated Jaffé-based creatinine methods compromises standardization and clinical reliability. Adoption of more specific methods and participation in clinically relevant EQA programs are essential to further strengthen laboratory quality and patient safety.
Related Concept Videos
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Acute Kidney Injury I: Introduction
Drug Dosing in Renal Diseases: Measurement of Glomerular Filtration Rate
Acute Kidney Injury III: Clinical Manifestations
Drug Dosing in Renal Diseases: Estimation of Glomerular Filtration Rate Based on Serum Creatinine Concentration
Serum Studies: Renal Function Tests